

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 85202086.6

(51) Int. Cl.<sup>4</sup>: C 07 D 307/79

(22) Date of filing: 16.12.85

C 07 D 317/66, C 07 D 405/12  
C 07 D 413/12, A 61 K 31/495

(30) Priority: 21.12.84 NL 8403918

(43) Date of publication of application:  
13.08.86 Bulletin 86/33

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: DUPHAR INTERNATIONAL RESEARCH B.V.  
C.J. van Houtenlaan 36  
NL-1381 CP Weesp(NL)

(72) Inventor: Kruse, Cornelis Gerrit  
c/o OCTROOIBUREAU ZOAN BV Apollolaan 151  
NL-1077 AR Amsterdam(NL)

(72) Inventor: van der Heyden, Johannes Antonius Maria  
c/o OCTROOIBUREAU ZOAN BV Apollolaan 151  
NL-1077 AR Amsterdam(NL)

(72) Inventor: van Wijngaarden, Ineke  
c/o OCTROOIBUREAU ZOAN BV Apollolaan 151  
NL-1077 AR Amsterdam(NL)

(72) Inventor: Hartog, Jan  
c/o OCTROOIBUREAU ZOAN BV Apollolaan 151  
NL-1077 AR Amsterdam(NL)

(72) Inventor: Olivier, Berend  
c/o OCTROOIBUREAU ZOAN BV Apollolaan 151  
NL-1077 AR Amsterdam(NL)

(74) Representative: Muis, Maarten et al,  
OCTROOIBUREAU ZOAN B.V. P.O. Box 140  
NL-1380 AC Weesp(NL)

(84) New pharmaceutical compositions having anti-psychotic properties.

(87) The invention relates to a group of new bicyclic hetero-aryl piperazine derivatives of formula 1. It was found that these compounds have interesting psychotropic in particular anti-psychotic properties.


The compounds can be prepared according to methods known for the synthesis of analogous compounds.

EP 0 190 472 A1

New pharmaceutical compositions having antipsychotic properties.

The invention relates to new pharmaceutical compositions having interesting psychotropic properties, notably antipsychotic properties, to new bicyclic heteroaryl piperazine derivatives which can be used in such compositions as the active substance and to the preparation of these compositions and compounds.

It was found that compounds of the general formula 1



in which

- A together with the two carbon atoms of the phenyl group forms an entirely or partly unsaturated cyclic group having 5-7 ring atoms with in the ring 1-3 hetero atoms from the group O, S and N, with the proviso that the sum of the number of oxygen atoms and sulphur atoms is at most 2, and that the nitrogen atoms in the ring may be substituted with a group  $R_4$  which may be hydrogen, alkyl, hydroxy-alkyl or acyl;
- B is an optionally branched or cyclic, saturated or (poly)unsaturated alkyl chain which may comprise one or more atoms from the group O and N in the chain or terminally and in which carbonyl groups, thiocarbonyl groups, sulphonyl groups or sulphonyl groups may also be present; the chain may moreover be substituted with one or more halogen atoms or with one or

more optionally substituted phenyl groups, hetero-aryl groups or heterocyclic groups; if the chain comprises a nitrogen atom, this is substituted with at least one group  $R_5$  which is an optionally substituted phenyl group or an alkyl group, cycloalkyl group, hydroxyalkyl group;

- $R_1$  and  $R_2$  may be alkyl, cycloalkyl, optionally substituted phenyl or heteroaryl, hydroxyalkyl, alkoxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, mono- or dialkylamino, mono- or diarylamino, hydroxyl, amino, alkyl-, alkoxy- or amino, or mono- or dialkylaminocarbonyl, nitro, cyano, halogen, trifluoromethyl, trifluoromethoxy, alkyl- or amino- or mono- or dialkylaminosulphonyl;  $R_2$  may moreover be an oxo group or thioxo group;  $m$  has the value 0-3 and  $p$  has the value 0-2; and

- $R_3$  is an alkyl group and  $n$  has the value 0-2, and the acid addition salts and prodrugs thereof have interesting psychotropic properties.

Compounds which are to be preferred on the basis of their properties are compounds of formula 1, in which the symbols have the following meanings:

-A forms together with the two carbon atoms of the phenyl group an entirely or partly unsaturated ring consisting of 5-atoms, which ring comprises at least one oxygen atom;

-B is straight, branched or cyclic alkyl, alkenyl, alkynyl, alkoxy- or hydroxyalkyl, aryl- or heteroaryl-alkyl, or a group of the formula  $-D-NR_5-CO-R_6$ , in which D is an optionally branched alkyl chain having at most 8 carbon atoms,  $R_5$  has the above meaning, and  $R_6$  is alkyl, cycloalkyl, a phenyl group substituted with a group  $R_1$ , in which  $R_1$  has the above-mentioned meaning, a saturated or non-saturated heterocyclic group, or  $R_5$  and  $R_6$  together with the group  $-NR_5-CO-$  form a heterocyclic system;

-R<sub>1</sub> and R<sub>2</sub> are alkyl, alkoxy, hydroxyl, nitro, cyano, halogen, trifluoromethyl, on the understanding that R<sub>1</sub> is in the meta- and/or para-position in relation to the piperazine group;

5 -m and p have the value 0-2; and

-n is 0.

When R<sub>1</sub>-R<sub>6</sub> is or comprises an alkyl group, this is preferably a straight or branched alkyl group having 1-5 carbon atoms.

10 As a cycloalkyl group, the groups R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub> and R<sub>6</sub> comprise a ring system having 3-7 ring atoms and not more than 10 carbon atoms as a whole.

When R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> or R<sub>5</sub> is a hydroxyalkyl group, such a group preferably comprises 1-5 carbon atoms. As a halogen atom, R<sub>1</sub>, R<sub>2</sub> preferably is fluorine, chlorine or bromine.

15 Optionally present hydroxyl or hydroxyalkyl groups may be esterified or etherified.

Compounds which are to be preferred in particular on the basis of their properties are:

- 20 a) 1-(benzo[b]furan-7-yl)-4-methylpiperazine;  
b) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;  
c) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;  
d) 1-(benzo[b]furan-7-yl)-4-(2-hydroxyethyl)piperazine;  
25 e) 1-(benzo[b]furan-7-yl)-4-propylpiperazine;  
f) 1-(benzo[b]furan-7-yl)-4-isopropylpiperazine;  
g) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-isopropylpiperazine;  
h) 1-(benzodioxol-4-yl)-4-isopropylpiperazine;  
i) 1-(benzo[b]furan-7-yl)-4-allylpiperazine;  
30 j) 1-(benzo[b]furan-7-yl)-4-propargylpiperazine;  
k) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-propargylpiperazine;  
l) 1-(benzodioxol-4-yl)-4-propargylpiperazine;  
m) 1-(benzo[b]furan-7-yl)-4-isobutylpiperazine;  
n) 1-(benzo[b]furan-7-yl)-4-cyclopropylmethylpiperazine;  
35 o) 1-(benzo[b]furan-7-yl)-4-pentylpiperazine;  
p) 1-(benzo[b]furan-7-yl)-4-[2-(2-furyl)ethyl]piperazine;

- q) 1-(benzo[b]furan-7-yl)-4-(4-chlorobenzyl)piperazine;  
r) 1-(benzo[b]furan-7-yl)-4-(2-phenylethyl)piperazine;  
s) 1-(benzo[b]furan-7-yl)-4-[2-[N-(acetyl)-N-(methyl)amino]ethyl]piperazine;  
5 t) 1-(benzo[b]furan-7-yl)-4-[2-[N-(pyrrolidin-2-onyl)]-ethyl]piperazine;  
u) 1-(benzo[b]furan-7-yl)-4-[2-(N-succinimidyl)ethyl]piperazine;  
v) 1-(benzo[b]furan-7-yl)-4-[2-[N-(oxazolidin-2-onyl)-ethyl]]piperazine;  
10 w) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-chlorobenzoyl)-N-(methyl)amino]ethyl]piperazine;  
x) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-cyanobenzoyl)-N-(methylamino)ethyl]piperazine;  
15 y) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-nitrobenzoyl)-N-(methyl)amino]ethyl]piperazine;  
z) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-methoxybenzoyl)-N-(methyl)amino]ethyl]piperazine;  
aa) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(methyl)amino]ethyl]piperazine;  
20 bb) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-[2-[N-(4-isopropylbenzoyl)-N-(methyl)amino]ethyl]piperazine;  
cc) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(2-hydroxyethyl)amino]ethyl]piperazine;  
25 dd) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(propyl)amino]ethyl]piperazine;  
ee) 1-(benzo[b]furan-7-yl)-4-[[N-methyl-5-(4-fluorophenyl)-pyrrol-2-yl]methyl]piperazine;  
ff) 1-(benzo[b]furan-7-yl)-4-(acetylmethyl)piperazine.

30 Suitable acids with which the compounds according to the invention can form pharmaceutically acceptable acid addition salts are, for example, hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, and organic acids such as citric acid, fumaric acid, maleic acid, tartaric acid, acetic acid, benzoic acid, p-toluenesulphonic acid, methanesulphonic acid, naphthalenesulphonic acid and  
35 the like.

Prodrugs are to be understood to be derivatives of the compounds of the formula (1) which are inactive as such, and which after administration are converted in the body into an active compound of formula (1).

5 When a centre of chirality is present, both the racemate and the individual enantiomers belong to the invention.

10 The compounds according to the invention have interesting psychotropic properties and may hence be used for the treatment of affections and diseases which are the result of disturbances in the central nervous system, for example psychoses, aggression, fear and depression.

15 The compounds notably have a specific antipsychotic activity which is not associated with the side effects as a result of dopaminolytic and sedative activities which generally are to be considered as undesired. Some compounds moreover have centrally mediated analgetic and/or antihypertensive properties, or have a thrombolytic effect.

20 The antipsychotic activity was determined in a test procedure in which the suppression of conditioned behaviour in experimental animals (rats) was measured in a manner known per se. The compounds were evaluated as active when in this test they show at least 50% suppression of the conditioned behaviour after oral administration of 25 50 mg per kg of body weight or less.

30 The dopaminolytic activity of the compounds was determined by means of behavioural or biochemical tests known per se, for example, induction of catalepsy, increase of the dopamine synthesis or conversion rate in the central nervous system, and by affinity to dopamine receptors which is determined by displacement of a radioactive labelled ligand in a tissue homogenate.

35 The sedative activity of the compounds was measured in a test in which their influence upon the spontaneous locomotoric activity of experimental animals is determined according to methods known per se.

It was found that the dopaminolytic and a dative side effects as a rule do not occur with dosages which are at least three times as high as those in which 50% suppression of the conditioned behaviour is found.

The quantity, frequency and way of administration may differ for each individual case, also dependent on the nature and the severity of the disturbances. In general, a dosage of 1-500 mg per day, and preferably 1-100 mg daily, may be used for humane applications in one dosage per day.


The active compounds according to the invention and their salts and prodrug forms can be processed to compositions by means of standard methods which are known per se, for example, pills, tablets, coated tablets, capsules, powders, injection liquids and the like, while using the usual auxiliary substances, for example, solid and liquid carrier materials.

The compounds and their acid addition salts, prodrugs and enantiomers can be brought into a form suitable for administration in a manner known per se.

The compounds of the formula (1) are new compounds with the exception of the compounds wherein A forms together with the two carbon atoms of the phenyl group a completely are partly unsaturated 5- or 6-membered ring which contains a nitrogen atom in the meta- or ortho-position in relation to the piperazine group as the only hetero atom,  $R_1$  is halogen, nitro or lower alkoxy,  $R_2$  is lower alkyl or an oxo group,  $n$  is 0,  $p$  is 0 or 1,  $m$  has the value 0-2, and B has the above mentioned meaning, which compounds are partly known from French patent specification 81,23744, Japanese patent specification 57,193459, British patent specification 2,086,896 and/or J. Chem. Soc., C, no. 10 (1967), pages 1003-1006.

The new compounds according to the invention can be prepared in a manner known for the synthesis of analogous compounds, for example, as described in Netherlands Patent Application 8005133.

The compounds can be obtained more in particular by  
 r action of a compound of formula 2



10 with a compound of formula L-B, in which A, B,  $R_1$ - $R_3$ ,  
m, n and p have the meanings mentioned hereinbefore, and L  
 is a so-called leaving group, for example hydroxyl, chlo-  
 15 rine, bromine or tosylate. This reaction may be carried  
 out both with and without an aprotic organic solvent, op-  
 tionally in the presence of an acid binder. Examples of  
 20 suitable solvents are methyl ethyl ketone, tetrahydrofu-  
 ran, acetonitril, dimethyl formamide, toluene and petro-  
 leum ether. As acid binders are to be considered substan-  
 ces can either be soluble or insoluble in the reaction  
 medium, for example, organic nitrogen bases, such as tri-  
 25 alkyl amines, pyridine, urea, and inorganic bases, such as  
 sodium or potassium carbonate or -bicarbonate. The reac-  
 tion temperature usually is between room temperature and  
 the reflux temperature of the solvent used, while the re-  
 action duration may vary from 1 to 20 hours.


25 Further the compounds of the invention of the formula  
 (1) can be obtained by reaction of a compound of the above  
 formula (2) with a carbonyl compound of the formula  $B' = O$   
 under the influence of a gentle reducing agent. In these  
 formulae A,  $R_1$ - $R_3$ , m, n and p have the above meaning  
 30 and  $B' = O$  results after the reaction in a group B having  
 the above meaning. This method is suitable in particular  
 for the preparation of compounds of formula (1) wherein B  
 represents a branched alkyl group or cycloalkyl group. The  
 reaction is preferably carried out in an alcoholic solvent  
 35 in the presence of a reduction agent which does not react



with the carbonyl group, such as metal borohydride, preferably sodium cyan borohydride. The reaction temperature is usually between 0°C and reflux temperature. The reaction time varies from a few minutes to several hours.

In so far as the starting compounds of formula 2 are new, they can be obtained according to methods which are known for the synthesis of analogous compounds, for example, according to methods which are known from Netherlands Patent Applications 80.05133 and 82.01708.


The compounds of formula 1 in which A,  $R_1$ - $R_3$ ,  $m$ ,  $n$  and  $p$  have the above-mentioned meanings and B is a group of the formula  $D-NR_5-CO-R_6$ , in which D,  $R_5$  and  $R_6$  have the above-mentioned meanings, with the proviso that  $R_5$  is not a phenyl group, are preferably prepared from the corresponding compound of formula 3,



by converting this with a compound  $L-R_5$ , in which A,  $R_1$ - $R_3$ , D, L,  $R_5$ ,  $R_6$ ,  $m$ ,  $n$  and  $p$  have the above-mentioned meanings. This reaction is preferably carried out in two steps. In the first step the proton of the nitrogen atom of the compound of formula 3 is removed by means of a strong organic base, for example, sodium hydride, potassium hydride or calcium hydride, or a sodium alkoxide or potassium alkoxide, preferably tert. butylate, in an aprotic organic solvent, for example, toluene, tetrahydrofuran, dimethylformamide or dimethylsulphoxide, at temperatures between -20°C and the reflux temperature of the solvent. In the second step the reagent  $L-R_5$  is added to the reaction mixture, the desired final product being usually obtained after a reaction time which varies from 5 minutes to a few hours.

A similar process can be used to convert compounds of the formula 3, wherein the group -NH- is replaced by a group -CH<sub>2</sub>-, and the other symbols have the above mentioned meanings.

These compounds in which A, R<sub>1</sub>-R<sub>3</sub>, m, n and p have the above-mentioned meanings and B is a group of the formula D-NR<sub>5</sub>-CO-R<sub>6</sub>, in which D, R<sub>5</sub> and R<sub>6</sub> have the above-mentioned meanings, may moreover be prepared from the corresponding compounds of formula 4,



by converting them with a compound E-CO-R<sub>6</sub>, in which A, R<sub>1</sub>-R<sub>3</sub>, D, R<sub>5</sub>, R<sub>6</sub>, m, n and p have the above-mentioned meanings and E is a leaving group, preferably of the type hydroxy, alkoxy, acyloxy, halogen, N-imidazolyl or N-triazolyl. This reaction is preferably carried out in an aprotic organic solvent, for example, those mentioned hereinbefore, in the presence of an acid binder, as mentioned hereinbefore, at temperatures between 0°C and the reflux temperature of the solvent used and a reaction duration which may vary from 5 minutes to a few hours.

A further suitable method for preparing some compounds of the formula (1) is reduction of a compound of the formula 1 wherein A, B, R<sub>1</sub>-R<sub>3</sub>, n, m and p have the above meanings on the understanding that B contains a carbonyl group directly attached to the piperazine nitrogen atom. This reaction can be carried out with reducing agents such as LiAlH<sub>4</sub> or a borane-complex like BH<sub>3</sub>.dimethylsulphide, in a suitable solvent, for example diethyl ether or tetrahydrofuran, at temperatures between 0°C and the reflux temperature of the solvent used. The reaction time is usually several hours.

In so far as the starting compounds of formulae 3 and 4 are new, they can be obtained in a manner analogous to the method described hereinbefore for the preparation of compounds of formula 1, starting with a compound of formula 2.

Compounds of the formula (1) can also be obtained from precursors having formula (1) in a way known per se, for example by using hydrogenation reactions or by reactions resulting in carbon atom - hetero atom bonds in chain B via nucleophilic substitution reactions whereby the reactant containing the hetero atom functions as nucleophile.

Furthermore, some compounds of formula 1 in which at least one of the groups B, R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> or R<sub>5</sub> comprises a hydroxyl function or in which B comprises an NH-R<sub>5</sub> group, can be prepared by splitting off in the last step a protective group, for example, an acetal, ketal, acyl, triphenyl methyl, trialkylsilyl, alkoxy- or trialkylsilylethyl- oxycarbonyl, by means of methods known for the purpose.

The invention will now be described in greater detail with reference to the following specific examples.


#### EXAMPLE I

1-benzo-[b]furan-7-yl-4[3-(4-fluorobenzoyl)propyl]piperazine HCL.


7.5 Mmol (1.79 g) of 1-benzo[b]furan-7-yl-piperazine HCl, together with 9.1 mmol (1.82 g) of 1-chloro-3-(4-fluorobenzoyl)-propane, 20 mmol (2.80 g) of potassium carbonate and a catalytic quantity (approximately 100 mg) of sodium iodide as a suspension in 50 ml of methyl ethyl ketone, was heated with thorough stirring so that the solvent refluxes. After stirring for 16 hours, 9.1 mmol of 1-chloro-3-(4-fluorobenzoyl)propane and 20 mmol of potassium carbonate were added again. After stirring for another 16 hours at reflux temperature, cooling, filtering and evaporating to dryness in vacuo were carried out. The

residue was chromatographed on silica gel with ethyl acetate as an eluent. After evaporating the fractions which comprised the desired product, material was obtained which was converted into the title compound via treatment with 1 equivalent of a HCl solution in ethyl acetate.

The compounds of formula 5A or 5B recorded in Table A were prepared in an analogous manner.



(5A)



(5B)

TABLE A

Comp. No.	Form. 5	R <sub>1</sub>	X	Salt	Melt. point. (°C)
1	A	H	methyl	HCl	240-244 (decomp.)
2	B	-	methyl	HCl	189-190
3	A	4-F	methyl	HCl	161-164,5
4	A	5-F	methyl	HCl	204-206,5
5	A	H	propargyl	HCl	204-205
6	B	-	propargyl	HCl	191-193
7	A	4-F	propargyl	HCl	184-185,5
8	A	H	allyl	HCl	208-208,5
9	A	H	n-propyl	HCl	210-211,5
10	A	H	2-hydroxyethyl	HCl	112-114
11	A	H	2-chloroethyl	HCl	230-231 (decomp.)
12	A	H	acetylmethyl	HCl	239-241 (decomp.)
13	A	H	n-pentyl	HCl	209-210
14	A	H	2-ethoxyethyl	HCl	128-132
15	A	H	benzyl	HCl	207,5-210
16	B	-	benzyl	base	60-62
17	A	H	4-chlorobenzyl	HCl	232-235 (decomp.)
18	A	H	2-phenylethyl	HCl	242-246
19	A	H	2-phenyloxyethyl	HCl	170-176





TABLE A (cont.)

Comp. No.	Form. 5	R <sub>1</sub>	X	Salt	Melt. point. (°C)
-----------	---------	----------------	---	------	----------------------







22	A	H		1,2 HCl	115-122 (decomp.)
23	A	H		base	viscous oil
24	A	H		base	118-125
				!	!
25	A	H		base	viscous oil
26	A	H		HCl	153-160 (decomp.)
27	A	H		HCl	+ 90

TABLE A (cont.)


Comp. No.	Form.	5	R <sub>1</sub>	X	Salt	Melt. point. (°C)
28	A		$\text{H}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\underset{\text{OH}}{\text{CH}}-\text{C}_6\text{H}_5$		HCl	180-183
29	A		$\text{H}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\underset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{C}_6\text{H}_4-\text{F}$		HCl	219-220
30	A		$\text{H}-\text{CH}_2-\text{CH}_2-\underset{\text{CH}_2-\text{C}_6\text{H}_4-\text{Cl}}{\overset{\text{CH}_3}{\text{N}}}$		HCl	229-231
31	A		$\text{H}-\text{CH}_2-\text{CH}_2-\underset{\text{CH}_3}{\overset{\text{O}}{\underset{\parallel}{\text{N}}}}-\text{C}_6\text{H}_4-\text{C}(\text{CH}_3)_2$		HCl	208-209
32	A		$\text{H}-\text{CH}_2-\text{CH}_2-\underset{\text{O}}{\underset{\parallel}{\text{N}}}-\text{C}_6\text{H}_4-\text{C}(\text{CH}_3)_2$		HCl	149-150

EXAMPLE II

1-B nzo[b]furan-7-yl-4-[2-[N-(4-isopropylbenzoyl)-N-(methylamino)ethyl]piperazine HCl.

5 A suspension of 75 mmol (8.55 g) of potassium hydride in mineral oil (35% KH) was washed three times with dry petroleum ether in a reaction vessel which was kept under an atmosphere of dry nitrogen. After pipetting the last quantity of petroleum ether, 70 ml of dry dimethylsulphoxide were slowly added dropwise, hydrogen gas escaping. After 10 15 minutes a solution of 59.2 mmol (23.2 g) of 1-benzo[b]furan-7-yl-4-[2-[N-(4-isopropylbenzoyl)amino]ethyl]piperazine in 140 ml of dry dimethylsulphoxide was rapidly added dropwise at a temperature of 20°C. A solution of 74 mmol (4.61 g) of methyl iodide in 50 ml of dry dimethylsulphoxide was added to the resulting yellow coloured solution at such a rate that the temperature of the reaction mixture remained below 30°C. After 30 minutes the reaction mixture was poured out on water, after which extraction with ethyl acetate was carried out. After drying these 20 extracts over magnesium sulphate, filtration and evaporation, a cloudy oil was obtained. It was taken up in approximately 800 ml of ethyl acetate and after filtration was treated with 1 equivalent of alcoholic HCl. The title compound started to crystallize out substantially immediately. After cooling, sucking off and drying, a white powder was obtained having a melting-point of 246-247°C (decomposition).

25 The compounds of formula 6A and B recorded in Table B hereinafter were prepared in an analogous manner.








TABLE B

Comp. No.	Form. 6	Y	Z	R <sub>1</sub>	R <sub>2</sub>	R <sub>5</sub>	R <sub>6</sub>	Salt	Melting point (°C)
33	B	-	O	-	-	CH <sub>3</sub>	4-fluorophenyl	HCl	190-192
34	A	CH	-	H	H	CH <sub>3</sub>	4-fluorophenyl	HCl	189-190
35	A	N	-	H	H	CH <sub>3</sub>	4-methylsulphonylphenyl	base	visc. oil
36	A	N	-	H	H	CH <sub>3</sub>	4-methylphenyl	HCl	240-241
37	A	N	-	H	H	CH <sub>3</sub>	4-tert.butylphenyl	HCl	240 (decomp.)
38	A	N	-	H	H	CH <sub>3</sub>	4-ethylphenyl	HCl	227-230 (decomp.)
39	A	N	-	H	H	CH <sub>3</sub>	phenyl	HCl	228-230
40	A	N	-	H	H	CH <sub>3</sub>	4-fluorophenyl	HCl	239-242 (decomp.)
41	A	N	-	H	H	CH <sub>3</sub>	4-chlorophenyl	HCl	239-240
42	A	N	-	H	H	CH <sub>3</sub>	4-trifluoromethylphenyl	HCl	250 (decomp.)
43	A	N	-	H	H	CH <sub>3</sub>	4-nitrophenyl	HCl	226-227, 5
44	A	N	-	H	H	CH <sub>3</sub>	4-dimethylaminophenyl	HCl	205-211 (decomp.)
45	A	N	-	H	H	CH <sub>3</sub>	4-methoxyphenyl	HCl	231-233
46	A	N	-	H	H	CH <sub>3</sub>	3-chlorophenyl	HCl	193-194
47	A	N	-	H	H	CH <sub>3</sub>	2-chlorophenyl	HCl	214-216
48	A	N	-	H	H	CH <sub>3</sub>	cyclohexyl	HCl	205-206
49	A	N	-	H	CH <sub>3</sub>	CH <sub>3</sub>	4-chlorophenyl	HCl	227-228
50	A	N	-	H	CH <sub>3</sub>	CH <sub>3</sub>	4-isopropylphenyl	HCl	192
51	A	N	-	5-F	H	CH <sub>3</sub>	4-chlorophenyl	HCl	219-222, 5
52	A	N	-	4-F	H	CH <sub>3</sub>	4-isopropylphenyl	HCl	244-249
53	A	N	-	H	H	C <sub>2</sub> H <sub>5</sub>	4-isopropylphenyl	HCl	203-204
54	A	N	-	H	H	C <sub>2</sub> H <sub>4</sub> OH	4-isopropylphenyl	HCl	137, 5-138
55	A	N	-	H	H	n-C <sub>3</sub> H <sub>7</sub>	4-isopropylphenyl	HCl	174-175
56	A	N	-	H	H	CH <sub>3</sub>	4-isopropylphenyl	HCl	246-247 (decomp.)
57	B	-	CH <sub>2</sub>	-	-	CH <sub>3</sub>	4-fluorophenyl	HCl	250-253

Example III

1-(Benzo[b]furan-7-yl-4-[2-[N-(acetyl)-N-methylamino]-ethyl]piperazine hydrochloride.

4.1 Mmol (0,62 ml) of triethylamine and 4,0 mmol (0,29 ml) of acetyl chloride were successively added to a solution of 3.7 mmol (0,96 g) of N-[2-[4-(benzo[b]furan-7-yl)-1-piperazinyl]ethyl]-N-methylamine in 50 ml of chloroform at room temperature, giving an exothermic reaction. After stirring for 15 minutes 5 ml of methanol was added and the mixture was sucked off to dryness in vacuo. The residue was treated with ether which resulted in crystallization of the obtained triethylamine hydrochloride. This was sucked off and washed with ether. The filtrate after evaporation was taken up in ethyl acetate. 1 Equivalent of hydrochloric acid was added, giving the title compound as a solid substance.

The compounds of formula 6A listed in table C were prepared in an analogous manner:

TABLE C

Comp. No.	Y	R <sub>1</sub>	R <sub>2</sub>	R <sub>5</sub>	R <sub>6</sub>	Salt	Melting point (°C)
58	N	H	H	CH <sub>3</sub>	methyl	HCl	192-193
59	N	H	H	CH <sub>3</sub>	ethoxy	HCl	hygroscopic
60	N	H	H	CH <sub>3</sub>	tert.-butyl	HCl	206-207
61	N	H	H	CH <sub>3</sub>	2-tetrahydrofuranyl	base	oil
62	N	H	H	CH <sub>3</sub>	4-cyanophenyl	HCl	230-237
63	N	H	H	CH <sub>3</sub>	3,4-dichlorophenyl	HCl	228-230
64	N	H	H	CH <sub>3</sub>	4-bromophenyl	HCl	127,5-128,5

Example IV1-(Benzo[b]furan-7-yl)-4-isopropylpiperazine hydrochlorid .

0.36 Ml of acetic acid, 0.52 g of sodium acetate and 1.0 ml of acetone were added successively to a solution of 6.28 mmol (1.50 g) of 1-(benzo[b]furan-7-yl)-piperazine hydrochloride in 20 ml of methanol at room temperature. After stirring for 30 minutes at room temperature 0.38 g of sodium cyanoborohydride were added to the reaction mixture and stirring was continued for 3 hours. After evaporation in vacuo the residue was purified by means of flash-chromatography on silica gel. The fractions containing the desired product were evaporated and the so-obtained free base was converted into the crystalline title compound by treatment with 1 equivalent of HCl in ethyl acetate.

The compounds of formulae 5A and 5B indicated in table D have been prepared in an analogous manner:

TABLE D

Comp. No.	Form. 5	R <sub>1</sub>	X	Salt	Melt. point (°C)
65	B	-	isopropyl	HCl	196-197
66	A	5-F	isopropyl	HCl	188-190, 5
67	A	H	isopropyl	HCl	+ 225
68	A	H	isobutyl	HCl	189.5-192
69	A	H	cyclohexyl	HCl	245-247

Example V1-(Benzo[b]furan-7-yl)-4-(cyclopropylmethyl)piperazine hydrochloride

0.28 g Of lithium aluminum hydride were added in small portions to a solution of 5.8 mmol (1.56 g) of 1-(benzo[b]furan-7-yl)-4-(cyclopropylcarbonyl)piperazine in 30

ml of dry tetrahydrofuran. The mixture was stirred until  
th formation of gas stopped. After adding of 5 ml of wa-  
ter and 50 ml of 2N sodium hydroxide the reaction mixture  
was extracted and the organic layers were evaporated.

5 Chromatographic purification on silica gel resulted in 1.0  
g of a viscous substance, which was converted into the  
title compound by treatment with 1 equivalent of HCl. in  
ethyl acetate.

10 The compounds of formula 5A mentioned in table E been  
prepared in similar way.

TABLE E

Comp. No.	R <sub>1</sub>	X	Salt	Melt. point (°C)
70	H	cyclopropylmethyl	HCl	204-206
71	H	2-(2-furyl)ethyl	HCl	236-241

20 Example VI




1-(Benzo[b]furan-7-yl)-4-[2-[N-(pyrrolidin-2-onyl)]-ethyl]-  
piperazine hydrochloride.

25 A suspension of 5 mmol (0.58 g) of potassium hydride in  
mineral oil (35% KH) was washed three times with dry pe-  
troleum ether in a reaction vessel which was kept under an  
atmosphere of nitrogen. Then 5 ml of dry dimethylsul-  
phoxide were added dropwise giving a clear solution. 4.15  
30 Mmol (0.315 ml) of 2-pyrrolidinon was added. After stir-  
ring for 20 minutes at room temperature 3.77 mmol (1.0 g)  
of 1-(benzo[b]furany-7-yl)-4-(2-chloroethyl)piperazine  
were added to the clear solution. After stirring for 16  
hours at room temperature and 1 hour at 70°C the mixture  
35 was poured out on a system of two phases consisting of  
water and ethylacetate. After extraction 1.10 g of an oil  
were obtained, which was purified by flash-chromatography

on silica g l. Th obtained substance (0.76 g) was converted with HCl in ethanol. The title compound was obtained after crystallization from a mixture of ethanol and ethyl acetate.


5 The compounds of the formula 5A mentioned in table F were prepared in a similar way:

TABLE F

10	Comp. No.	R <sub>1</sub>	X	Salt	Melt. point (°C)
15	72	H		1.5HCl	223-224
20	73	H		2HCl	138 (decomp.)
25	74	H		base	152-153

CLAIMS:

1. Pharmaceutical composition which comprises a bicyclic heteroaryl piperazine derivative as the active substance, characterized in that it comprises as the active substance a compound of the formula 1



10 wherein:

-A together with the two carbon atoms of the phenyl group forms an entirely or partly unsaturated cyclic group having 5-7 ring atoms with in the ring 1-3 hetero atoms from the group O, S and N, with the proviso that the sum of the number of oxygen atoms and sulphur atoms is at most 2, and that the nitrogen atoms in the ring may be substituted with a group  $R_4$  which may be hydrogen, alkyl, hydroxy-alkyl or acyl;

15 -B is an optionally branched or cyclic, saturated or (poly)unsaturated alkyl chain which may comprise one or more atoms from the group O and N in the chain or terminally and in which carbonyl groups, thiocarbonyl groups, suphynyl groups or sulphonyl groups may also be present; the chain may moreover be substituted with one or more halogen atoms or one or more optionally substituted phenyl groups, heteroaryl groups or heterocyclic groups; if the chain comprises a nitrogen atom, this is substituted with at least one group  $R_5$  which is an optionally substituted phenyl group or an alkyl group, cycloalkyl group, hydroxyalkyl group;

20 - $R_1$  and  $R_2$  may be alkyl, cycloalkyl, optionally substituted phenyl or heteroaryl, hydroxyalkyl, alkoxy-

alkyl, alkoxy, aryloxy, alkylthio, arylthio, mono- or dialkylamino, mono- or diarylamino, hydroxyl, amino, alkyl-, alkoxy- or amino- or mono- or dialkylaminocarbonyl, nitro, cyano, halogen, trifluoromethyl, trifluoromethoxy, alkyl- or amino- or mono- or dialkylaminosulphonyl;  $R_2$  may moreover be an oxo group or thioxo group;  $m$  has the value 0-3 and  $p$  has the value 0-2; and

- $R_3$  is an alkyl group and  $n$  has the value 0-2, or an acid addition salt or prodrug thereof.

2. A composition according to claim 1 characterized in that it comprises a compound of the formula (1), in which:

-A forms together with the two carbon atoms of the phenyl group an entirely or partly unsaturated ring consisting of 5-atoms, which ring comprises at least one oxygen atom;

-B is straight or branched or cyclic alkyl, alkenyl, alkynyl, alkoxy- or hydroxyalkyl, aryl- or heteroarylalkyl, or a group of the formula  $-D-NR_5-CO-R_6$ , in which D is an optionally branched alkyl chain having at most 8 carbon atoms,  $R_5$  has the above meaning, and  $R_6$  is alkyl, cycloalkyl, a phenyl group substituted with a group  $R_1$ , in which  $R_1$  has the above-mentioned meaning, a saturated or non-saturated heterocyclic group, or  $R_5$  and  $R_6$  together with the group  $-NR_5-CO-$  form a heterocyclic system;

- $R_1$  and  $R_2$  are alkyl, alkoxy, hydroxyl, nitro, cyano, halogen, trifluoromethyl, on the understanding that  $R_1$  is in the meta- and/or para-position in relation to the piperazine group;

- $m$  and  $p$  have the value 0-2, and

- $n$  is 0,

or an acid addition salt or prodrug thereof as the active component.



3. Composition according to claim 1, characterized in that it contains:

- a) 1-(benzo[b]furan-7-yl)-4-methylpiperazine;
- b) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;
- 5 c) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;
- d) 1-(benzo[b]furan-7-yl)-4-(2-hydroxyethyl)piperazine;
- e) 1-(benzo[b]furan-7-yl)-4-propylpiperazine;
- f) 1-(benzo[b]furan-7-yl)-4-isopropylpiperazine;
- 10 g) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-isopropylpiperazine;
- h) 1-(benzodioxol-4-yl)-4-isopropylpiperazine;
- i) 1-(benzo[b]furan-7-yl)-4-allylpiperazine;
- j) 1-(benzo[b]furan-7-yl)-4-propargylpiperazine;
- k) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-propargylpiperazine;
- 15 l) 1-(benzodioxol-4-yl)-4-propargylpiperazine;
- m) 1-(benzo[b]furan-7-yl)-4-isobutylpiperazine;
- n) 1-(benzo[b]furan-7-yl)-4-cyclopropylmethylpiperazine;
- o) 1-(benzo[b]furan-7-yl)-4-pentylpiperazine;
- p) 1-(benzo[b]furan-7-yl)-4-[2-(2-furyl)ethyl]piperazine;
- 20 q) 1-(benzo[b]furan-7-yl)-4-(4-chlorobenzyl)piperazine;
- r) 1-(benzo[b]furan-7-yl)-4-(2-phenylethyl)piperazine;
- s) 1-(benzo[b]furan-7-yl)-4-[2-[N-(acetyl)-N-(methyl)amino]ethyl]piperazine;
- t) 1-(benzo[b]furan-7-yl)-4-[2-[N-(pyrrolidin-2-onyl)]-ethyl]piperazine;
- 25 u) 1-(benzo[b]furan-7-yl)-4-[2-(N-succinimidyl)ethyl]piperazine;
- v) 1-(benzo[b]furan-7-yl)-4-[2-[N-(oxazolidin-2-onyl)-ethyl]]piperazine;
- 30 w) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-chlorobenzoyl)-N-(methyl)amino]ethyl]piperazine;
- x) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-cyanobenzoyl)-N-(methyl)amino]ethyl]piperazine;
- y) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-nitrobenzoyl)-N-(methyl)amino]ethyl]piperazine;
- 35 z) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-methoxybenzoyl)-N-(methyl)amino]ethyl]piperazine;

- aa) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-is propylbenzoyl)-  
-N-(methyl)amino]ethyl]piperazine;  
bb) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-[2-[N-(4-isopropyl-  
benzoyl)-N-(methyl)amino]ethyl]piperazine;  
5 cc) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-  
-(2-hydroxyethyl)amino]ethyl]piperazine;  
dd) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-  
-(propyl)amino]ethyl]piperazine;  
10 ee) 1-(benzo[b]furan-7-yl)-4-[[N-methyl-5-(4-fluorophenyl)-  
-pyrrol-2-yl]methyl]piperazine;  
ff) 1-(benzo[b]furan-7-yl)-4-(acetylmethyl)piperazine.  
and acid addition salts and prodrugs thereof.

4. A method of preparing pharmaceutical compositions by  
bringing a bicyclic heteroarylpiperazine derivative in a  
15 manner know per se into a form suitable for administra-  
tion, characterized in that at least one compound of for-  
mula (1), an acid addition salt or prodrug thereof is used  
as the active substance.

20 5. A method of treating affections and diseases which  
are the result of disturbances in the central nervous sys-  
tem, characterized in that a composition as claimed in  
Claim 1 is used.

25 6. Compounds of the formula (1), wherein A, B,  $R_1$ -  
 $R_3$ , m, n and p have the meanings given in claim 1, acid  
addition salts and prodrugs thereof, with the exception of  
the compounds wherein A forms together with the two carbon  
atoms of the phenyl group a completely are partly unsatu-  
30 rated 5- or 6-membered ring which contains a nitrogen atom  
in the meta- or ortho-position in relation to the piper-  
azine group as the only hetero atom,  $R_1$  is halogen, ni-  
tro or lower alkoxy,  $R_2$  is lower alkyl or an oxo group,  
n is 0, p is 0 or 1, m has the value 0-2, and B has the  
above meaning.


35 7. Compounds of the formula (1), wherein A, B,  $R_1$ -  
 $R_3$ , m, n and p have the meanings given in claim 2, acid  
addition salts and prodrugs thereof.

8. Compound selected from the group consisting of:

- 5 a) 1-(benzo[b]furan-7-yl)-4-methylpiperazine;  
b) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;  
c) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-methylpiperazine;  
d) 1-(benzo[b]furan-7-yl)-4-(2-hydroxyethyl)piperazine;  
e) 1-(benzo[b]furan-7-yl)-4-propylpiperazine;  
f) 1-(benzo[b]furan-7-yl)-4-isopropylpiperazine;  
g) 1-[5-fluoro(benzo[b]furan-7-yl)]-4-isopropylpiperazine;  
h) 1-(benzodioxol-4-yl)-4-isopropylpiperazine;  
10 i) 1-(benzo[b]furan-7-yl)-4-allylpiperazine;  
j) 1-(benzo[b]furan-7-yl)-4-propargylpiperazine;  
k) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-propargylpiperazine;  
l) 1-(benzodioxol-4-yl)-4-propargylpiperazine;  
m) 1-(benzo[b]furan-7-yl)-4-isobutylpiperazine;  
15 n) 1-(benzo[b]furan-7-yl)-4-cyclopropylmethylpiperazine;  
o) 1-(benzo[b]furan-7-yl)-4-pentylpiperazine;  
p) 1-(benzo[b]furan-7-yl)-4-[2-(2-furyl)ethyl]piperazine;  
q) 1-(benzo[b]furan-7-yl)-4-(4-chlorobenzyl)piperazine;  
r) 1-(benzo[b]furan-7-yl)-4-(2-phenylethyl)piperazine;  
20 s) 1-(benzo[b]furan-7-yl)-4-[2-[N-(acetyl)-N-(methyl)amino]ethyl]piperazine;  
t) 1-(benzo[b]furan-7-yl)-4-[2-[N-(pyrrolidin-2-onyl)]-ethyl]piperazine;  
u) 1-(benzo[b]furan-7-yl)-4-[2-(N-succinimidyl)ethyl]piperazine;  
25 v) 1-(benzo[b]furan-7-yl)-4-[2-[N-(oxazolidin-2-onyl)-ethyl]piperazine;  
w) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-chlorobenzoyl)-N-(methyl)amino]ethyl]piperazine;  
30 x) 1-benzo[b]furan-7-yl)-4-[2-[N-(4-cyanobenzoyl)-N-(methylamino]ethyl]piperazine;  
y) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-nitrobenzoyl)-N-(methylamino]ethyl]piperazine;  
35 z) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-methoxybenzoyl)-N-(methylamino]ethyl]piperazine;

- aa) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(methylamino)ethyl]piperazine;
- bb) 1-[4-fluoro(benzo[b]furan-7-yl)]-4-[2-[N-(4-isopropylbenzoyl)-N-(methylamino)ethyl]piperazine;
- cc) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(2-hydroxyethyl)amino]ethyl]piperazine;
- dd) 1-(benzo[b]furan-7-yl)-4-[2-[N-(4-isopropylbenzoyl)-N-(propylamino)ethyl]piperazine;
- ee) 1-(benzo[b]furan-7-yl)-4-[[N-methyl-5-(4-fluorophenyl)-pyrrol-2-yl]methyl]piperazine;
- ff) 1-(benzo[b]furan-7-yl)-4-(acetylmethyl)piperazine.

9. A method of preparing bicyclic heteroarylpiperazine derivatives in a manner known for the synthesis of analogous compounds, characterized in that compounds of formula (1), in which A, B,  $R_1$ - $R_3$ ,  $m$ ,  $n$  and  $p$  have the meanings given in Claim 1, and acid addition salts and prodrugs thereof, are prepared by reaction of a compound of formula 2




with a compound of formula L-B, in which A, B,  $R_1$ - $R_3$ ,  $m$ ,  $n$  and  $p$  have the above-mentioned meanings, and L is a leaving group.

10. A method as claimed in claim 9, characterized in that compounds of the formula (1), in which the symbols have the meanings given in claim 1 are prepared by reacting a compound of formula (2), with a compound of formula  $B'=0$  in the presence of a reducing agent, in which formulae A,  $R_1$ - $R_3$ ,  $m$ ,  $n$  and  $p$  have the above meaning and  $B'$  after reaction gives a group B of the above meaning.


11. A method as claimed in Claim 9, characterized in that compounds of formula (1), in which A,  $R_1$ - $R_3$ ,  $m$ ,  $n$  and  $p$  have the meanings given in Claim 1, and B is a group

of the formula  $D-NR_5-CO-R_6$ , in which  $D$ ,  $R_5$  and  $R_6$  have the meanings given in Claim 2, with the proviso that  $R_5$  cannot be phenyl, and acid addition salts and pro-drugs thereof, are prepared by converting the corresponding compound of formula 3



with a compound of the formula  $L-R_5$ , in which  $A$ ,  $D$ ,  $R_1-R_3$ ,  $R_5$ ,  $R_6$ ,  $m$ ,  $n$  and  $p$  have the above-mentioned meanings, and  $L$  is a leaving group.

12. A method as claimed in Claim 9, characterized in that a compound of formula 1 is prepared, in which  $A$ ,  $R_1-R_3$ ,  $m$ ,  $n$  and  $p$  have the meanings given in Claim 1 and  $B$  is a group of the formula  $-D-NR_5-CO-R_6$ , in which  $D$ ,  $R_5$  and  $R_6$  have the meanings given in Claim 2, by converting a compound of formula 4



with a compound  $E-CO-R_6$ , in which  $E$  is a leaving group.

13. A method as claimed in Claim 9, characterized in that a compound of formula 1 is prepared by reduction of a compound of the formula (1), wherein  $A$ ,  $R_1-R_3$ ,  $n$ ,  $m$  and  $p$  have the meaning given in Claim 1, and  $B$  contains a carbonyl group which is attached to the piperazine nitrogen atom.

14. A method as claimed in claim 9, characterized in that a precursor of a compound of the formula (1) is hydrogenated in a way known per se, or is reacted with a nucleophile containing a hetero atom in a way known per

s resulting in a bond between a carbon atom and a hetero atom.

5 15. A method as claimed in Claim 9, characterized in that a compound of formula 1 is prepared in which at least one of the groups B, R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, or R<sub>5</sub> is a hydroxyalkyl group, or in which B contains a group NH-R<sub>5</sub>, by removing, as the last step, a protective group or protective groups in a manner known per se.

10

15



European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**  
which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

**0190472**

Application number

**EP 85 20 2086**

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
D,X	GB- A- 2 097 790 (DELALANDE S.A.)  * The whole document * ---	1-15	C 07 D 307/79 C 07 D 317/66 C 07 D 405/12 C 07 D 413/12 A 61 K 31/495
D,X	JOURNAL OF THE CHEMICAL SOCIETY, section C, no. 10, 1967, pages 1003-1008, London, GB; D.P. AINSWORTH et al.: "Syntheses of heterocyclic compounds. Part XVII. 4-Nitroindoles and nitrophe- nylpyrazolones with tertiary amine substituents in the benzene ring"  * The whole article * ---	9-15	
Y	EP- A- 0 000 121 (MERCK)  * The whole document * ---	1-15	
Y	COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 40, no. 5, ./.		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 D 307/00 C 07 D 317/00 C 07 D 405/00 C 07 D 413/00 A 61 K 31/00
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-4, 6-15</p> <p>Claims searched incompletely:</p> <p>Claims not searched: 5</p> <p>Reason for the limitation of the search:</p> <p>Method for treatment of the human or animal body by surgery or therapy, see article 52(4) of the European Patent Convention.</p>			
Place of search The Hague		Date of completion of the search 25-03-1986	Examiner ALLARD
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>			

EPO Form 1606.1 (03/82)



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

0190472

Application number

EP 85 20 2086

- 2 -

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	May 1975, pages 1612-1622, Prague, CS; I. CERVENA et al.: Naphthylpiperazines and tetralylpiperazines: Synthesis and pharmacological properties"		
	* The whole article *	1-15	
	---		
D,X	GB- A- 2 086 896 (OTSUKA PHARMACEUTICAL)		
	* The whole document *	1-4	
	---		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
D,X	CHEMICAL ABSTRACTS, vol. 99, no. 11, September 12, 1983, page 574, abstract no. 88225e, Columbus, Ohio, US; & JP - A - 57 193 459 (OTSUKA PHARMACEUTICAL CO.) 27-11-1982		
	* Abstract *	1-4	
	---		
X	US- A- 3 808 212 (E.O. RENTH)		
	* The whole document *	1-15	
	---		
D,X	EP- A- 0 048 045 (DUPHAR)		
	* The whole document *	1-15	
	---		
P,X	EP- A- 0 138 280 (DUPHAR)		
	* The whole document *	1-15	
	-----		